Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageProgyny is a global leader in women’s health and family building solutions. We envision a world where everyone can realize their dreams of family and ideal health. Our mission is to empower healthier, supported journeys through transformative fertility, family building and women’s health benefits. Through our differentiated approach to benefits plan design, member education and support and active network management, our clients’ employees are able to pursue the most effective treatment across life’s milestones from the best providers and specialists and achieve optimal outcomes.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Business segments
Jun 2026 · $350.5MThe company’s own SEC segment disclosure.
- Fertility Benefit Services$230.2M66%
- Pharmacy Benefit Services$120.3M34%
Progyny, Inc. (PGNY) reported revenue of $329M in Q1 2026 (quarter ended Mar 31, 2026), up 1.4% from the same quarter a year earlier. That came with a gross margin of 25% and net income of $24M (7.4% of revenue). For the full year FY2025, revenue was $1.29B (+10% year on year) and net income $59M. Its largest product in Jun 2026 was Fertility Benefit Services at $230M, 66% of the disclosed total, well ahead of Pharmacy Benefit Services at 34%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.